Related Experiment Video
Updated: May 7, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
Increased plasma norepinephrine levels in previously pre-eclamptic women
K H Lampinen1, M Rönnback2, P-H Groop2
11] Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland [2] Folkhälsan Research Center, Biomedicum, Helsinki, Finland [3] Department of Obstetrics and Gynecology, Karolinska, Stockholm, Sweden.
Journal of Human Hypertension
|September 20, 2013
Summary
Women with a history of pre-eclampsia show sustained higher plasma norepinephrine levels years later. This may contribute to their increased cardiovascular disease risk.
Area of Science:
- Cardiovascular Medicine
- Obstetrics and Gynecology
- Endocrinology
Background:
- Previous pre-eclampsia is linked to increased cardiovascular morbidity through unknown mechanisms.
- Understanding these mechanisms is crucial for early intervention and risk reduction.
Purpose of the Study:
- To determine if plasma norepinephrine (NE) levels remain elevated 5-6 years post-pre-eclampsia.
- To investigate associations between NE levels and cardiovascular disease risk factors: insulin sensitivity, vascular function, and arterial pressure.
Main Methods:
- Compared 28 women with prior pre-eclampsia to 20 controls.
- Measured resting and standing blood pressure (BP), plasma NE and endothelin-1 (ET-1) levels.
- Assessed insulin sensitivity, vascular function (venous occlusion plethysmography, pulse wave analysis), and 24-hour BP.
Main Results:
- Women with previous pre-eclampsia had significantly higher resting plasma NE levels (P=0.02).
- No significant associations were found between NE levels and insulin sensitivity, vasodilatory capacity, or 24-hour BP/heart rate.
- Endothelin-1 levels were similar, but correlated with upright BP in the pre-eclampsia group.
Conclusions:
- Elevated plasma NE levels persist years after pre-eclampsia.
- Sustained higher NE may be a contributing factor to the heightened cardiovascular disease risk observed in women with a history of pre-eclampsia.
Related Concept Videos
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Increased Intracranial Pressure ll: Pathophysiology
Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:14Increased Intracranial Pressure l: Introduction
Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component expands, CSF and venous blood...